GMP‐Compliant Process for the Manufacturing of an Extracellular Vesicles‐Enriched Secretome Product Derived From Cardiovascular Progenitor Cells Suitable for a Phase I Clinical Trial
Journal of Extracellular Vesicles · 2025-08 · 14 (8)
DOI: 10.1002/jev2.70145 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Journal of Extracellular Vesicles, online erschienen am 20.08.2025. Verfasst von Camille Humbert und 14 weiteren Autor:innen. Beteiligte Einrichtung: Centre MEARY de Thérapie Cellulaire et Génique de l'Assistance Publique - Hôpitaux de Paris (AP-HP), Direction de la Recherche Clinique et de l'Innov…. Hauptthemen laut MEDLINE: Extracellular Vesicles, Secretome, Stem Cells. Die Arbeit wurde bisher 75-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Assistance Publique - Hôpitaux de Paris, FUJIFILM Cellular Dynamics, Inc., Programme Hospitalier de Recherche Clinique - National.
Abstract (Originalsprache)
Extracellular vesicle (EV)‐enriched secretomes are emerging as a new and innovative therapeutic option in the field of regenerative medicine. The clinical use of EV‐enriched secretome‐based products requires manufacturing processes and quality control (QC) testing that comply with current good manufacturing practice (GMP). The goal of this work was to develop a robust and reproducible large‐scale GMP‐compliant process for the production of an EV‐enriched secretome derived from cardiovascular progenitor cells (CPC), including the vesiculation of CPC, purification and concentration of the product; and sterilising filtration. QC strategies for in‐process and release testing of an investigational medicinal product (IMP) were developed to guarantee quantity, safety, purity and identity. The IMP showed biological activity and was non‐immunogenic in vitro, and showed no signs of toxicity or tumour development in vivo. The IMP was approved for use in a single‐centre Phase I clinical trial by the French National Agency for Medicines and Health ( ANSM ) for the treatment of heart failure. The IMP is stored between –65°C and –85°C and can be easily diluted by the hospital pharmacy for infusion to the patient. This work represents a major advance for the use of CPC derived EV‐enriched secretomes as a biological drug for cardiac clinical applications. Trial Registration : ClinicalTrials.gov identifier: NCT05774509
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre MEARY de Thérapie Cellulaire et Génique de l'Assistance Publique - Hôpitaux de Paris (AP-HP), Direction de la Recherche Clinique et de l'Innovation (DRCI), Paris, France.
- FUJIFILM Cellular Dynamics, Inc. (FCDI), Madison, Wisconsin, USA.
- Paris Centre de Recherche Cardiovasculaire (PARCC), Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Cité, Paris, France.
- Institut Curie, Université Paris Sciences & Lettres (PSL), Centre de Recherche, CurieCoreTech Spectrométrie de Masse Protéomique, Paris, France.
- Université Paris Cité, INSERM, Centre d'Investigation Clinique de Biothérapie (CIC-BT) CBT501, Paris, France.
- Département Essais Cliniques, DRCI, AP-HP, Agence Générale des Equipements et Produits de Santé (AGEPS), Paris, France.
ORCID-Profile: Camille Humbert, Damarys Loew
Förderung
- Assistance Publique - Hôpitaux de Paris
- FUJIFILM Cellular Dynamics, Inc.
- Programme Hospitalier de Recherche Clinique - National
Zitieren
APA
Humbert, C., Cordier, C., Drut, I., Hamrick, M., Wong, J., Bellamy, V., Flaire, J., Bakshy, K., Dingli, F., Loew, D., Larghero, J., Fabreguettes, J. R., Menasché, P., Renault, N. K., & Churlaud, G. (2025). GMP‐Compliant Process for the Manufacturing of an Extracellular Vesicles‐Enriched Secretome Product Derived From Cardiovascular Progenitor Cells Suitable for a Phase I Clinical Trial. Journal of Extracellular Vesicles, 14(8). https://doi.org/10.1002/jev2.70145
Vancouver
Humbert C, Cordier C, Drut I, Hamrick M, Wong J, Bellamy V, et al. GMP‐Compliant Process for the Manufacturing of an Extracellular Vesicles‐Enriched Secretome Product Derived From Cardiovascular Progenitor Cells Suitable for a Phase I Clinical Trial. Journal of Extracellular Vesicles. 2025;14(8). doi:10.1002/jev2.70145
BibTeX
@article{Humbert2025,
author = {Humbert, Camille and Cordier, Chloé and Drut, Iouri and Hamrick, Michele and Wong, Jacquelyn and Bellamy, Valérie and Flaire, Justine and Bakshy, Kiranmayee and Dingli, Florent and Loew, Damarys and Larghero, Jérôme and Fabreguettes, Jean-Roch and Menasché, Philippe and Renault, Nisa K and Churlaud, Guillaume},
title = {GMP‐Compliant Process for the Manufacturing of an Extracellular Vesicles‐Enriched Secretome Product Derived From Cardiovascular Progenitor Cells Suitable for a Phase I Clinical Trial},
journal = {Journal of Extracellular Vesicles},
year = {2025},
volume = {14},
number = {8},
doi = {10.1002/jev2.70145}
}
EUVIMED